Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 11/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496031 | 1.00 | GRM2 (0.82) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1496376 | 0.90 | GRM2 (1.00) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1496317 | 0.90 | GRM2 (1.00) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL30120569 | 0.90 | GRM2 (1.00) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1496321 | 0.90 | GRM2 (1.00) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL6884741 | 0.88 | GRM2 (0.89) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL10324288 | 0.88 | GRM2 (0.89) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1495854 | 0.88 | GRM2 (0.88) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1495851 | 0.88 | GRM2 (0.88) | GRM2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL3139919 | 0.84 | GRM2 (0.71) | GRM2KDM4EMAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051331-B2 | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2015-06-09 | — | — | US | claimed |
| EP-2477994-B1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-12-11 | — | — | EP | claimed |
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-19 | — | — | US | claimed |
| US-9051331-B2 | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2015-06-09 | — | — | US | disclosed |
| EP-2477994-B1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-12-11 | — | — | EP | disclosed |
| EP-2477994-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| WO-2011034830-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184566-A1 | SUBSTITUTED DIHYDRO BENZOCYCLOALKYLOXYMETHYL OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | GRM2 1/4885KDM4E 1067/4885MAPT 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.